Invenra launched its B-Body Express Antibody Expression service, which enables biotechnology and pharmaceutical companies to rapidly access the company’s B-Body bispecific antibody platform, the company announced recently.

“Advancing bispecific programs requires both speed and access to platforms engineered for developability,” Invera CEO Dr. Roland Green said in a statement. “Our B-Body Express service provides exactly that.”

B-Body Express features accelerated production, rapid turnaround, full yield delivery and a simple licensing path.

The company plans to expand the B-Body Express service to include standardized 2×1 and 2×2 B-Body formats in the near future.

The B-Body platform provides bispecific antibody yield, conventional purification, high solubility, subcutaneous-compatible viscosity and stability in both discovery and scale-up.